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Background: Thyroid nodules are common, but only 5% of nodules are found to be malignant. In North America,
the incidence of thyroid cancer is increasing. Fine needle aspirate (FNA) biopsy is the diagnostic test of choice.
Unfortunately, up to 20% of FNAs are non-diagnostic. A specific molecular marker for thyroid cancer is desirable.
Evidence suggests that cell signaling through transforming growth factor beta (TGF- β) is important in the development
of thyroid cancer. We sought to compare the expression of TGF- β in malignant and benign thyroid nodules.
Methods: From 2008-present, thyroid nodule tissue from thyroidectomy specimens was prospectively collected and
stored at −80°C. RNA extraction and reverse transcription was performed on 47 samples (24 papillary thyroid cancer
and 23 benign nodules). Quantitative PCR using SYBR green was performed to detect TGF-β-1 and −2. Resulting CT
values were normalized against β-actin. Gene expression was calculated using the 2-ΔCT method.
Results: A significantly greater expression of TGF- β1 (p < 0.0001) was detected in the group of malignant thyroid
nodules compared to benign nodules. There was no difference in the expression of TGF- β2 (p = 0.4735) between the
two groups.
Conclusions: In this study, we demonstrated that expression of TGF- β1 but not TGF- β2 is significantly increased in
papillary thyroid cancer compared to benign thyroid nodules. This may serve as a potential diagnostic marker for
papillary thyroid cancer.
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Thyroid cancer is an uncommon malignancy; however,
its incidence has increased by an average of 6.8% per
year for males and 8.8% for females between 1998 and
2007 in Canada [1]. Papillary thyroid cancer (PTC) ac-
counts for over 80% of all thyroid cancer cases [2]. Des-
pite well-defined histological parameters, thyroid cancer
patients do not have specific clinic presentations other
than palpable nodules. An accurate clinical diagnosis
prior to surgery has proven difficult due to the lack of
specific diagnostic tests for thyroid cancer.* Correspondence: Robert.Hart@cdha.nshealth.ca
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reproduction in any medium, provided the orFine needle aspiration (FNA) biopsy is a commonly
used diagnostic technique for thyroid nodules; however,
up to 20% of initial FNAs are non-diagnostic. Of these
2-51% will be malignant [3-5]. Current recommenda-
tions in the management of patients with non-diagnostic
FNAs advocate repeating the FNA, or pursuing hemi-
thyroidectomy for definitive pathological diagnosis [2,4].
Consequently, a large portion of thyroid surgery (40-
60%) is performed on what is later diagnosed as benign
disease [4-6]. Development of reliable and accurate pre-
operative diagnostic tests to differentiate thyroid cancer
from benign thyroid nodules is critical to reduce un-
necessary cost to our health care system, and potential
patient morbidity.
The transforming growth factor β (TGF-β) cytokine
family contains 33 members, of which, three TGF-βtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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genic proteins, and growth differentiation proteins [7-10].
TGF-β achieves intracellular signaling via phosphorylation
of the Smad2 and Smad3 proteins which complex with
Smad4 and translocate to the nucleus to regulate gene ex-
pression [7-12]. In PTC cell lines and animal models,
TGF-β signaling has been shown to regulate cellular epi-
thelial to mesenchymal transition [10,12,13]. Embryologic-
ally, TGF-β acts as a potent inducer of apoptosis,
fundamental to normal development [9]. In adult cells,
TGF-β retains its effect as a potent inducer of apoptosis,
and also acts to promote immune regulation and angio-
genesis, acting as a tumor suppressor gene [8,9,11,12].
In cancer, animal models demonstrate that the role of
TGF-β is complicated. TGF-β initially retains its tumor
suppressor properties, but, as cells lose their response to
apoptotic signals during tumor development, TGF-β be-
comes a tumor promoter gene [8-11]. Through the addi-
tive effect of immune suppression, promotion of
angiogenesis, and epithelial to mesenchymal transition,
TGF-β acts to promote invasive tumors with a propen-
sity for metastasis. In situ hybridization and immunohis-
tochemical studies on human thyroid tissues have
previously demonstrated increased TGF-β in thyroid
cancer, and in some instances, in multinodular goiter
[7,10,14,15].
In this pilot study, we endeavored to determine whether
or not in vivo expression of TGF-β1 and TGF-β2 in hu-
man thyroid nodules differed between patients with PTC
and those with benign nodular changes.
Materials and methods
Patient selection and sample collection
Ethics approval for this study was obtained through Capital
Health Halifax’s ethics department. Informed consent
allowing the collection and storage of resected thyroid
tissue was obtained from patients’ preoperatively.
From Nov 2008 to present, all patients presenting to the
department of Otolaryngology-Head and Neck Surgery at
the Victoria General Hospital (Halifax, Canada) for thy-
roid surgery were asked to participate in this study. Exclu-
sion criteria included: 1) completion hemi-thyroidectomy,
2) blood-borne infectious disease, and, 3) diagnosis of a
non-PTC. Patients and tissue samples were sequentially
assigned anonymous identifying numbers.
At the time of surgery, the pathological specimen of
resected thyroid tissue was sent fresh from the operating
theater to the pathology department where the dominant
nodule margins were inked. A portion of the dominant
nodule was then either snap frozen in liquid nitrogen or
placed in RNAlater (Ambion) in a 2 ml micro centrifuge
tube. Samples were stored at −80°C.
Final pathology reports were reviewed and thyroid spec-
imens were grouped as either benign nodular changes orPTC. Twenty-three benign tissue samples and twenty-four
tumor samples were then retrieved from storage for RNA
extraction.
RNA extraction and reverse transcription
Working on ice in a class II biological safety cabinet
(SteriGuard III Advance, Baker Company, Sanford, ME)
a portion of each frozen tissue sample was removed (ap-
proximately 3 mm × 3 mm) with a sterile no. 10 surgical
blade in a sterile tissue culture dish. This represented
approximately 60 mg of tissue. The tissues were homog-
enized (PowerMax AHS 200®) in a 3.5 ml Röhre tube
(Sarstedt) containing 600 μl of Buffer RLT (RNeasy® Plus
Mini Kit, Qiagen) with 1% (6 μl) β-mercaptoethanol.
The lysate was centrifuged for 3 minutes at 3273 × g.
RNA was isolated using the RNeasy® Plus Mini Kit (Qia-
gen) according to the manufacturer’s instructions. The
final RNA elution was carried out with 50 μl of RNase-
free water passed twice through the RNeasy® spin column.
Sample RNA was quantified using an Epoch® plate
reader using a Take3® plate and Gen5® software (version
1.10.8). Reverse transcription was carried out using the
QuantiTect® Reverse Transcription Kit (Qiagen) accor-
ding to the manufacturer’s instructions. Briefly, approxi-
mately 2 μg of template RNA per sample was used in a
reaction volume of 40 μl. The cDNA synthesis was con-
ducted at 42°C for 30 minutes and stopped by incubat-
ing the reaction mixture at 95°C for 3 minutes. Samples
were then stored at −20°C.
Real-time PCR
A total of 1 μl template cDNA per reaction was amplified
by real-time PCR in a 7900HT Fast Real-Time PCR Sys-
tem (Applied Biosystems; SDS 2.2.2) using RT2 SYBR®
Green ROX™ qPCR Mastermix (Qiagen) with the follow-
ing primers: beta-actin forward 5′-AGC GGG AAA TCG
TGC GTG -3′ and reverse 5′-CAG GGT ACA TGG
TGG TGC C-3′; TGF-β1 as published [16], and TGF-β2
forward 5′-AAGTCATACCACCTTTCCGATTG-3′ and
reverse 5′-GACGGCACAGGGATTTCTTCT-3′. An ini-
tial denaturation step of 95°C for 10 minutes was carried
out to activate the HotStart® Taq DNA polymerase (Qia-
gen), this was followed by 40 cycles of denaturation at 95°
C × 15 seconds and a combined annealing and elongation
step of 60°C for 60 seconds. Each sample was run in tripli-
cate with each primer pair. The AutoCT algorithm of the
program determined the baseline and threshold of Ct
value for each primer pair. Samples with a Ct value >35
were rejected.
Statistical analysis
The sample mRNA expression level of TGF-β1 and
TGF-β2 was assessed by averaging the triplicate CT
values. Gene expression profiles were expressed using
Table 2 Patient demographics of thyroid nodules
analyzed
Group M:F Age (range) n
B 1:2.28 58.83(32–81) 23
PTC 1:1.67 53.83 (35–77) 24
Total 56.27 47
PTC = Papillary thyroid cancer; B = Benign; M:F =male: female ratio;
n = group size.
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-Δ C
T ) method. The ΔCT was calcu-
lated using β-actin as an internal control according to
Equation 1 [17]. Non-parametric analysis utilizing the
Mann–Whitney U-test was carried out using SPSS soft-
ware version 20 (SPSS Inc., Chicago, IL) to compare the
TGF-β1 and TGF-β2 ΔCT values between benign and
malignant nodules. Significance was set at a P-value of
0.05.
ΔCT ¼ 2− CT gene of interest − CT control geneð Þ ð1Þ
Results
Patient selection and sample collection
At the time of the study a total of 273 patients were
asked to participate. Of these, 87 patients either refused
participation or were excluded. From the remaining pa-
tients, a total of 186 thyroid samples were collected and
stored. The groups’ demographics are summarized in
Table 1. Average age of patients diagnosed with papillary
cancer was 67.3 years old. The male: female ratio in this
cancer group was 1:1.5. Tissue from 106 of these sam-
ples was available for this study. The remaining 80 sam-
ples had been used in prior experiments. Of the 186
surgeries performed, 103 (55%) were diagnosed as be-
nign after pathological examination. Table 2 summarizes
the demographics of patients whose tissues were ana-
lyzed in this study.
Real time PCR
Amplified sample cDNA was quantified via the afore-
mentioned ΔCT method. The range of gene specific ΔCT
values, in benign vs. PTC nodules, is demonstrated in
Table 3.
Non-parametric statistics
Mann–Whitney U-tests revealed significantly increased
expression of TGFβ-1 (p < 0.0001), but not TGFβ-2 (p =
0.4735), in PTC nodules compared to benign nodules.
Results are shown in Figure 1.
Discussion
Thyroid nodules are common, affecting 4-7% of the US
population, and thyroid cancer most often presents as a
nodule. However, only 5% of nodules are found to beTable 1 Thyroid study patient demographics
Group M:F Age (range) n
B 1:2.81 43.5(26–81) 103
PTC 1:1.51 67.3 (18–80) 83
Total 54.15 186
Thyroid samples were grouped according to pathological diagnoses: Benign
(B) and papillary thyroid cancer (PTC). Average age (and range), male: female
ratio (M:F), and group size (n) are shown.malignant. Thyroid cancer represents 2.5% of all malig-
nancies [2], but the rate of thyroid cancer in Canada is
steadily increasing at approximately 7% per year for
males and 9% per year for females [1]. PTC accounts for
approximately 80% of thyroid malignancies [2].
Fine needle aspirate (FNA) biopsies for cytological
examination represents the first line investigation for
thyroid nodules. For PTC, the accuracy of FNA cytology
is 99%. However, approximately 20% of FNAs are non-
diagnostic [2,5]. Attaining an accurate preoperative diag-
nosis of a thyroid nodule can prove difficult due to the
lack of specific diagnostic tests for thyroid cancer. Con-
sequently, 40-60% of thyroid surgery is performed for
diagnostic purposes after non-diagnostic FNA cytology
[4-6]. A specific molecular marker for thyroid cancer
screening is desirable to avoid the resource burden of
potentially avoidable surgery.
In this pilot study, a thyroid nodule database and tis-
sue bank was used to identify and group patients based
on their diagnoses; these included benign nodules and
PTC. We demonstrated that in the Nova Scotia popula-
tion sampled, the average age of patients presenting for
thyroid surgery, and patients diagnosed with thyroid
cancer, is 54.5 and 67.3 years respectively. This repre-
sents an older cancer cohort than the traditionally taught
45–49 year old female. Additionally the male: female ratio
for PTC is usually quoted as 1:3 [2]. We noted a slight in-
crease in the number of men with PTC in our database,
with a male: female ratio of 1:1.5. Whether this is due to
sampling error or represents a true trend is yet to be
discerned.
In total, 186 surgeries were performed, 103 (55%) for
benign disease. Again, this highlights the burden of diag-
nostic thyroid surgery on operating room and in-patient
resources. A recent cost analysis simulation examined
the expected cost savings with the utilization of a diag-
nostic molecular marker for thyroid cancer in cases of
indeterminate FNA cytology. Assuming a sensitivity andTable 3 Range of group specific 2-ΔCT values for TGF- β1
and TGF- β2 in thyroid nodules
Group TGF-β1 2-Δ CT range TGF-β2 2
-Δ C
T range
PTC 7.74 x 10−4 - 1.80 x 10−1 1.39 x10−5 - 3.96 x 10−4
B 4.65 x 10−3 - 4.15 x 10−2 6.55 x 10−6 - 3.80 x 10−4
PTC = Papillary thyroid cancer; B = Benign; TGF = Transforming growth factor.
Figure 1 Mann–Whitney U-test analysis of 2-Δ CT values. A) Significantly increased expression of TGFβ-1 mRNA in the PTC (cancer) group is
observed (p < 0.0001). B) No significant difference in TGFβ-2 expression is observed (p = 0.4735).
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such a marker would result in a savings of $1087 in dir-
ect costs per patient as well as a significant gain in qual-
ity adjusted life years [4]. Costs to a publicly funded
health care system were not addressed. However, in a re-
cent publication from our department, the cost of an in-
patient hospital bed was calculated to equal $1245 per
day, with the OR fees amounting to $565 per hour be-
fore factoring nursing costs [18]. Clearly, substantial po-
tential cost savings exist in the setting of improved
preoperative diagnostic abilities.
TGF-β is a cytokine found to play a role in PTC. It rep-
resents a potential diagnostic molecular marker for the
disease. Immunohistochemical studies examining the role
of TGF-β in human thyroids and thyroid cancer have
demonstrated increased cytoplasmic presence of TGF-β at
the periphery of poorly circumscribed PTC. These tumors
were associated with increased invasiveness and metasta-
sis with an increased propensity towards epithelial to mes-
enchymal transition [8,10,13]. The association of TGF-β
with epithelial to mesenchymal transition in PTC has been
replicated in animal and in vitro studies [8,13]. Addition-
ally, oligonucleotide microarray studies of papillary thy-
roid tumor samples have demonstrated increased TGF-β
expression [14]. TGF-β effects are context specific, acting
as a potent anti-tumor agent as well as a pro-oncogenic
agent depending on the stage and tumor type. In normal
thyroid tissue, the effects of TGF-β are anti-proliferation,
pro-apoptotic, and repressive to both thyroglobulin and
sodium-iodine symporter (NIS) expression [12,19]. In
vitro studies have demonstrated loss of pro-apoptotic re-
sponse to TGF-β in thyroid cancer cells. This leads to
tumor promotion by TGF-β, postulated to be via the com-
bined effects of immune suppression, angiogenesis and
epithelial to mesenchymal transition [8,11-13,19].
In this pilot study, we examined the TGF-β1 and TGF-
β2 expression level in 23 cases of human PTC. These
were compared to nodules with benign changes on path-
ology. Utilizing real-time quantitative PCR and reverse
transcription techniques, our data strongly demonstrated
that in the presence of PTC, TGF-β1 mRNA levels aresignificantly elevated compared to glands with benign
nodular changes. There was no difference in the expres-
sion of TGF-β2 seen between the two groups. This up-
regulation of TGF-β1 gene expression is consistent with
previous findings utilizing differing molecular and stain-
ing techniques [7,10,14,15]. TGF-β1 but not TGF-β2 ap-
pears to be a promising molecular marker potentially
exploitable for the diagnosis of PTC in thyroid nodules.
Currently, commercial RNA-based gene expression
classifiers are available for molecular marker testing of
thyroid nodules with indeterminate cytology [20,21].
The American Thyroid Association recommends use of
molecular marker testing for nodules with indeterminate
cytology with a specific focus on expression of BRAF,
RAS, RET/PTC, PAX8-PPARγ, and galectin-3 [22]. One
commercially available array Afirma™, lists a total 167
genes in its classifier, however, TGF- β1 is not included
[20]. The addition of testing with the current Afirma™
gene classifier has demonstrated detection of benign
nodules in 52% of indeterminate nodules, thus prevent-
ing further diagnostic surgery in approximately half of
the patients tested [23]. The results of our study suggest
that analysis of TGF- β1 expression in addition to these
currently screened genes may serve to further refine
gene classifiers in future microarrays in order to improve
the detection of benign nodules. Further investigation is
needed in this regard.
The results of our current study were significant in
demonstrating increased expression of TGF-β1 in PTC.
However, our conclusions are limited by our sample size
and by potential sampling bias. As noted, 80 collected
samples were unavailable for this study. This may have po-
tentially skewed our data. Nonetheless, we are reassured
by the fact that our results appear to be congruent with
the findings of previous authors’ in vitro work on PTC cell
lines, animal models, and immunohistological studies
[7,8,10,14,15]. We did not observe a difference in TGF-β2
expression between benign and malignant nodules.
To our knowledge, this study is the first to examine a
fresh frozen human thyroid tissue bank and to demon-
strate the significantly elevated expression of TGF-β1,
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nign thyroid nodules. Future work with our expanding
thyroid tissue bank will facilitate elucidating the role of
TGF-β1 in both PTC genesis and diagnosis.
Conclusion
Our study has demonstrated that, in the Nova Scotia
population presenting to our department, approximately
55% of the thyroid surgery performed is for benign thy-
roid changes. The average age of presentation with a
malignant nodule is 67.3 years, while the average age of
all comers presenting with a thyroid mass is 54.5 years.
The proportion of men diagnosed with thyroid cancer
compared to women is 1:1.5 respectively.
In those cases of PTC examined, TGF-β1 expression was
significantly increased compared to thyroids with benign
disease. Interestingly, TGF-β2 expression did not differ be-
tween the groups. TGF-β has been shown in multiple pre-
vious studies to play a role in PTC, however, to date no
studies examining the potential use TGF-β1 as a cytological
diagnostic marker for PTC have been completed. Future
experiments examining this application are pending. The
results of which will likely translate into significant cost-
and resource-savings for our health care system.
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